👋 Good morning! Xaira Therapeutics raised $1 billion and then… went quiet. No splashy pipeline reveals. No constant press cycle. Just a lot of curiosity about what exactly they were building behind the curtain.

Now we have an answer and it’s a big one. The company just unveiled X-Cell, an AI-powered “virtual cell” trained on one of the largest genome-wide perturbation datasets ever assembled. Instead of just observing biology, the model is designed to predict what happens when you actually change it.

That’s the shift. Most biological data tells us what is. Xaira is chasing the why and the what happens next. Early signals suggest X-Cell can predict outcomes beyond the data it was trained on, which is exactly the kind of leap drug discovery has been waiting for.

If this works, it’s not replacing scientists. It’s giving them a cheat code.

🦾 Roche Loads Up 3,500 GPUs to Build an AI Drug Factory
Roche is going all-in on AI infrastructure, expanding its Nvidia partnership to build what it calls the largest hybrid-cloud AI factory in pharma. The setup now includes 3,500 GPUs spread across the U.S. and Europe, powering everything from drug discovery to diagnostics and manufacturing. The goal is simple: run more experiments, faster, and with better predictive power. With Genentech’s “Lab-in-the-Loop” strategy feeding real-world data back into models, Roche is trying to collapse the gap between computation and biology. The AI arms race is no longer theoretical, it’s hardware.

💊 J&J Lands FDA Approval for $5B+ Psoriasis Pill
Johnson & Johnson just scored FDA approval for Icotyde, a once-daily IL-23 oral peptide that could shake up the psoriasis market. In trials, around 70% of patients achieved clear or nearly clear skin, with over half hitting PASI 90 by week 16. That puts it ahead of existing oral competitors and positions it as a serious alternative to injectable biologics. Analysts are already projecting multi-billion-dollar peak sales. After years of needles dominating this space, the pill era is officially knocking.

☢️ TerraPower Bets $450M on Nuclear Cancer Supply Chain
TerraPower Isotopes is dropping $450 million to build a massive actinium-225 manufacturing facility in Philadelphia, aiming to become the world’s top supplier of the rare isotope powering next-gen radiopharmaceuticals. The site will span 250,000 square feet and could increase production capacity 20-fold when combined with expansions in Washington. With demand for targeted radiotherapies heating up, supply has quietly become one of the biggest bottlenecks. TerraPower is positioning itself as the tollbooth.

🛑 FTC Blocks Alcon Deal, Forces $356M Exit
Alcon is walking away from its planned $356 million acquisition of Lensar after the FTC stepped in with antitrust concerns. Regulators argued the deal would eliminate competition in a market already benefiting from price wars and rapid innovation. Alcon pushed back but ultimately decided the time and cost of the fight were not worth it. It’s the second M&A setback this year for the company, and a reminder that regulators are paying very close attention to consolidation in medtech.

🫀 FDA Clears First Device for Aortic Regurgitation.
JenaValve’s Trilogy system becomes the first minimally invasive implant approved for severe aortic regurgitation, avoiding open-heart surgery.

💸 Lilly-Backed Startup Raises $68.7M for T Cell Engagers.
Shanghai-based Excalipoint launches with six oncology assets targeting hard-to-treat cancers.

🎯 Pfizer CDK4 Inhibitor Hits Phase 2 Endpoint.
Atirmociclib improves progression-free survival in metastatic breast cancer, with eyes already on earlier lines of treatment.

⚖️ Judge Blocks RFK Jr. Vaccine Overhaul.
A federal ruling halts major changes to the U.S. vaccine schedule, citing unlawful decision-making.

🗽 J&J Shuts Down NYC Incubator.
After hosting 100+ startups, JLABS New York transitions operations back to the New York Genome Center.

🧠 Parkinson’s Cell Therapy Shows Early Promise.
Aspen’s autologous neuron therapy improves symptoms across all patients after one year.

📉 Bicycle Therapeutics Cuts 30% of Workforce.
The biotech shelves its lead program and slashes costs to extend runway through 2030.

While everyone is busy watching GLP-1s print money, a quieter shift is underway. Some of pharma’s most reliable revenue engines are about to fall off a cliff.

In 2026, a wave of blockbuster drugs will lose U.S. exclusivity, opening the door to generics, biosimilars, and a whole lot of revenue erosion. These aren’t flashy newcomers. They’re the steady, cash-flow machines that have been quietly funding pipelines for years.

Here’s the actual lineup hitting the cliff:

• Xolair — asthma & chronic urticaria | Roche/Novartis | $3.7B U.S. sales
• Pomalyst — multiple myeloma | Bristol Myers Squibb | $2.3B U.S. sales
• Opsumit — pulmonary arterial hypertension | Johnson & Johnson | $1.6B U.S. sales
• Janumet/Januvia — type 2 diabetes (combo) | Merck | $1.3B U.S. sales
• Simponi — autoimmune diseases | Johnson & Johnson | $1.2B U.S. sales
• Mavenclad — multiple sclerosis | Merck KGaA | $716M U.S. sales
• Gattex — short bowel syndrome | Takeda | $707M U.S. sales
• Trintellix — major depressive disorder | Lundbeck/Takeda | $698M U.S. sales
• Briviact — epilepsy | UCB | $652M U.S. sales
• Xeljanz — autoimmune diseases | Pfizer | $625M U.S. sales

Normally, this is where biosimilars flood in and prices drop. But here’s the twist. That wave isn’t fully forming.

Executives across companies like Teva and Sandoz are increasingly talking about a “biosimilar void.” For several of these biologics, there simply aren’t ready-to-launch competitors waiting in the wings. Manufacturing complexity, regulatory hurdles, and thinner margins have slowed development pipelines.

That creates a strange middle ground. Revenues decline, but not as fast as expected. Competition exists, but not enough to fully reshape markets overnight.

For pharma, this is both a risk and an opportunity. Legacy products lose exclusivity, but the absence of immediate competition can soften the blow. For biosimilar players, it’s an open invitation to step in and build the next wave of competition.

Either way, the industry is about to relearn a familiar lesson. Blockbusters don’t last forever. But the aftershocks of their decline can still be profitable.

That’s how many high-wage life science jobs Indiana is aiming to create with a $1 billion state-backed initiative. The plan leans on tax incentives and existing pharma giants to turn the state into a Midwest biotech hub.

Here’s what biotech Redditors are talking about:

📩 The Nobel Laureate Actually Replied
One student emailed a Nobel laureate on a whim and got a reply in four hours. The takeaway wasn’t just surprise, it was a reminder that the people at the top of science are often more approachable than expected. Strip away the titles and you still have someone who just likes talking biology.

😰 Coping With the Biotech Job Market
Another thread captured the opposite end of the spectrum. Professionals stuck in draining jobs, navigating a brutal hiring market, and debating whether to stay put or risk jumping ship. The consensus was simple: when the market tightens, people settle. And coping starts to look a lot like building a life outside of work.

😳 GSK Accused of Gaming Asthma Drug Market.
A Senate report claims decades of tactics kept Flovent prices high while limiting competition and access.

📉 Analysts Say Lilly Stock Is “Priced to Perfection.”
Concerns grow that obesity drug hype leaves little room for execution missteps.

🧪 FDA Opens Door to Animal Testing Alternatives.
New guidance allows organoids and computational models even without full prior validation.

🧠 Biomarkers Could Redefine Psychiatry.
Researchers push for diagnostic tools that move beyond symptom-based mental health care.

🎯 R1 Therapeutics Targets Kidney Disease With $77.5M Debut
R1 Therapeutics is emerging from stealth with $77.5 million to tackle chronic kidney disease in dialysis patients, starting with a licensed asset targeting phosphate imbalance. The approach aims to replace decades-old phosphate binders that suffer from poor adherence and tolerability issues. With millions of patients affected globally and limited innovation in the space, R1 is betting that a more patient-friendly therapy can unlock a large, underserved market.

🎉 March 19 — Taxonomists Get Their Flowers
Today marks Taxonomist Appreciation Day, founded in 2013 to recognize the scientists who name and classify life on Earth. It’s not the flashiest job in science, but it underpins everything from drug discovery to conservation. No taxonomy, no framework. No framework, no biology as we know it.

Some scientists are building virtual cells that can predict biology. Others are still naming the organisms that make biology possible.

One group is simulating the future. The other is organizing reality.

Both are essential. One just gets a lot more VC funding.

We’re off next week (Wooo), but we’ll be back March 31 with more biotech chaos, breakthroughs, and probably at least one billion-dollar surprise. 👋

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead